 IRVINE, Calif., Feb. 09, 2021 GLOBE NEWSWIRE -- Oncocyte Corporation NYSE American: OCX, a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the closing the sale of 8,947,000 shares of its common stock at a public offering price of 4.50 per share in its previously announced underwritten public offering, including 1,167,000 shares sold upon the exercise in full of a 15 over-allotment option by the underwriters. The gross proceeds to the Company from this offering were approximately 40.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The offering closed on February 9, 2021. 